secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2022-11-28T23:59:59+00:00
Accession:  0001193125-22-292939
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Selecta Biosciences appoints Blaine Davis as CFO, replacing Kevin Tan
---------------------------------------------------------------------

- Blaine Davis named CFO effective Nov 28, 2022; Kevin Tan stepped down amicably.
- Davis receives $440,000 base salary, 40% target bonus, and option for 1,250,000 shares vesting over 4 years.
- Tan receives full 2022 bonus and equity vesting through Jan 4, 2023 per separation agreement.
- Davis previously CFO at Protara Therapeutics; over 25 years biopharma finance experience.
- Company highlights upcoming Phase 3 gout readout, Phase 1/2 MMA trial, and IL-2 candidate selection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000119312522292939/0001193125-22-292939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000119312522292939/d405812d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-292939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer